Gain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson’s Models

Reuters11-20

Gain <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson's Models

Gain Therapeutics Inc. announced new preclinical data on its lead drug candidate, GT-02287, at the Society for Neuroscience annual meeting, Neuroscience 2025, held November 15-19 in San Diego, CA. The results, presented in a poster session, demonstrated GT-02287's mechanism of action in facilitating the trafficking of glucocerebrosidase (GCase) to mitochondria and lysosomes. The data showed that GT-02287 reduced mitochondrial stress, enhanced neuronal survival in rat dopaminergic neurons, and decreased MIRO1 staining in a mouse model of Parkinson's disease, suggesting improved mitochondrial health. Additionally, the compound improved mitochondrial function in patient-derived fibroblasts with GBA1 mutations. The findings support GT-02287's potential as a disease-modifying therapy for Parkinson's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579463-en) on November 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584369631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584369631","market":"nz","top_or_hot":-1,"title":"Gain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson’s Models","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Gain <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson's Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gain Therapeutics Inc. announced new preclinical data on its lead drug candidate, GT-02287, at the Society for Neuroscience annual meeting, Neuroscience 2025, held November 15-19 in San Diego, CA. The results, presented in a poster session, demonstrated GT-02287's mechanism of action in facilitating the trafficking of glucocerebrosidase (GCase) to mitochondria and lysosomes. The data showed that GT-02287 reduced mitochondrial stress, enhanced neuronal survival in rat dopaminergic neurons, and decreased MIRO1 staining in a mouse model of Parkinson's disease, suggesting improved mitochondrial health. Additionally, the compound improved mitochondrial function in patient-derived fibroblasts with GBA1 mutations. The findings support GT-02287's potential as a disease-modifying therapy for Parkinson's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579463-en) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson’s Models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson’s Models\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Gain <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson's Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gain Therapeutics Inc. announced new preclinical data on its lead drug candidate, GT-02287, at the Society for Neuroscience annual meeting, Neuroscience 2025, held November 15-19 in San Diego, CA. The results, presented in a poster session, demonstrated GT-02287's mechanism of action in facilitating the trafficking of glucocerebrosidase (GCase) to mitochondria and lysosomes. The data showed that GT-02287 reduced mitochondrial stress, enhanced neuronal survival in rat dopaminergic neurons, and decreased MIRO1 staining in a mouse model of Parkinson's disease, suggesting improved mitochondrial health. Additionally, the compound improved mitochondrial function in patient-derived fibroblasts with GBA1 mutations. The findings support GT-02287's potential as a disease-modifying therapy for Parkinson's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579463-en) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL7LzDZd:1","article_id":"2584369631","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584369631","pubTimestamp":1763640020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Gain Therapeutics Inc. announced new preclinical data on its lead drug candidate, GT-02287, at the Society for Neuroscience annual meeting, Neuroscience 2025, held November 15-19 in San Diego, CA. The results, presented in a poster session, demonstrated GT-02287's mechanism of action in facilitating the trafficking of glucocerebrosidase  to mitochondria and lysosomes. The data showed that GT-02287 reduced mitochondrial stress, enhanced neuronal survival in rat dopaminergic neurons, and decreased MIRO1 staining in a mouse model of Parkinson's disease, suggesting improved mitochondrial health. Additionally, the compound improved mitochondrial function in patient-derived fibroblasts with GBA1 mutations. The findings support GT-02287's potential as a disease-modifying therapy for Parkinson's disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","BK4139":"生物科技","GANX":"Gain Therapeutics, Inc.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Gain Therapeutics公布临床前数据显示GT-02287可增强帕金森模型中的线粒体功能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"GANX":0.9},"content_text":"Gain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson's Models\n    \n\n        Gain Therapeutics Inc. announced new preclinical data on its lead drug candidate, GT-02287, at the Society for Neuroscience annual meeting, Neuroscience 2025, held November 15-19 in San Diego, CA. The results, presented in a poster session, demonstrated GT-02287's mechanism of action in facilitating the trafficking of glucocerebrosidase (GCase) to mitochondria and lysosomes. The data showed that GT-02287 reduced mitochondrial stress, enhanced neuronal survival in rat dopaminergic neurons, and decreased MIRO1 staining in a mouse model of Parkinson's disease, suggesting improved mitochondrial health. Additionally, the compound improved mitochondrial function in patient-derived fibroblasts with GBA1 mutations. The findings support GT-02287's potential as a disease-modifying therapy for Parkinson's disease.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579463-en) on November 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584369631","isCrawlerRequest":true}